Latest & greatest articles for bronchiolitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bronchiolitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bronchiolitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Bronchiolitis

Bronchiolitis is mainly caused by the respiratory syncytial virus (RSV). The virus travels down to the bronchioles in the lungs causing them to become inflamed making it difficult to breath.

Almost every child will be infected with RSV by the time they reach two years. Adults can also contract the virus, typically during winter months.

In mild cases bronchiolitis will clear up without treatment. The virus that causes bronchiolitis travels through tiny droplets of liquid and can be passed through the air or contracted by touching infected surfaces.

Symptoms include: Sore throat, dry cough, blocked nose and aches and pains throughout the body.

Although there is no cure for chronic bronchiolitis research and clinical studies on bronchiolitis suggest that some lifestyle changes can ease symptoms: avoid smoking, eat a healthy diet and maintain regular exercise. In extreme cases steroids can be prescribed to help minimise inflammation.

Read more on medications used to treat bronchiolitis and the causes of the virus.

Top results for bronchiolitis

61. Do Febrile Infants Aged 60 to 90 Days With Bronchiolitis Require a Septic Evaluation?

Do Febrile Infants Aged 60 to 90 Days With Bronchiolitis Require a Septic Evaluation? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2012

62. Systematic review and meta-analysis: Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions

Systematic review and meta-analysis: Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions Article Text Therapeutics Systematic review and meta-analysis Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions Shawn Ralston Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2012

63. Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis

Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2011

64. Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan.

Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. BACKGROUND: In this descriptive case series, 80 soldiers from Fort Campbell, Kentucky, with inhalational exposures during service in Iraq and Afghanistan were evaluated for dyspnea on exertion that prevented them from meeting the U.S. Army's standards for physical fitness. METHODS: The soldiers underwent extensive evaluation of their medical and exposure history, physical examination, pulmonary-function testing (...) who underwent lung biopsy, all biopsy samples were abnormal, with 38 soldiers having changes that were diagnostic of constrictive bronchiolitis. In the remaining 11 soldiers, diagnoses other than constrictive bronchiolitis that could explain the presenting dyspnea were established. All soldiers with constrictive bronchiolitis had normal results on chest radiography, but about one quarter were found to have mosaic air trapping or centrilobular nodules on chest CT. The results of pulmonary-function

NEJM2011 Full Text: Link to full Text with Trip Pro

65. Inhaled Epinephrine, Steroids for Bronchiolitis

Inhaled Epinephrine, Steroids for Bronchiolitis Inhaled Epinephrine, Steroids for Bronchiolitis – TheNNTTheNNT Inhaled Epinephrine with or without Steroids for Bronchiolitis 15 for admission In Summary, for those who received the epinephrine with/without the steroids: Benefits in NNT 94.1% saw no benefit 5.9% were helped (epinephrine alone) by preventing hospital admission (day 1) 1 in 17 were helped (epinephrine alone) (hospitalization prevented, day 1) Harms in NNT None were harmed (...) by medication side effects None were harmed (medication side effects) View As: NNT % Source: Efficacy Endpoints: Admission Rate (Day 1) Harm Endpoints: None Narrative: Bronchiolitis, a viral respiratory infection in the first 2 years of life (most commonly caused by respiratory syncytial virus) often leads to significant use of healthcare resources. Optimal management strategies remain unclear, including pharmacotherapy for wheezing and shortness of breath. This Cochrane review identified and assessed six

theNNT2011

66. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis

Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, Klassen TP, Vandermeer B CRD summary The authors concluded (...) that adrenaline with or without dexamethasone appeared beneficial and safe for short-term outcomes in young children outpatients with bronchiolitis, but further research is needed. There was no clear benefit from any intervention among inpatients. The low quality and short duration of included trials, and uncertainties surrounding statistical analyses, mean the authors' conclusions should be interpreted with caution. Authors' objectives To compare the safety and efficacy of bronchodilators and steroids, alone

DARE.2011

67. Nebulized Hypertonic Saline for Bronchiolitis

Nebulized Hypertonic Saline for Bronchiolitis Nebulized Hypertonic Saline for Bronchiolitis – TheNNTTheNNT Nebulized Hypertonic Saline for Bronchiolitis in Infants 1 less hospital day In Summary, for those who received the nebulized hypertonic saline: Benefits in NNT Hospitalized infants were helped by a 1-day decrease in their hospital stay Harms in NNT None were harmed View As: NNT % Source: Efficacy Endpoints: Duration of Hospital Stay, Decrease in Clinical Severity Scores, Decrease (...) in Admission Rates Harm Endpoints: Tachycardia, Hypertension, Pallor, Tremor, Nausea, and Vomiting Narrative: Acute bronchiolitis is the one of the most common respiratory infections in infants. It affects the lower respiratory tract and is usually caused by a virus, with respiratory syncytial virus (RSV) being the most common pathogen. It is estimated that nearly all infants are infected with RSV and that between 1 and 2% of these develop symptoms severe enough to warrant admission. While the use

theNNT2011

68. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses Journals Library An error has occurred in processing the XML document An error occurred retrieving

NIHR HTA programme2011

69. WITHDRAWN: Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing.

WITHDRAWN: Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. BACKGROUND: Acute bronchiolitis in infants and young children is associated with long-term airway disease also known as post-bronchiolitic wheezing. Two major hypotheses have been proposed to explain the association between bronchiolitis and PBW. The first hypothesis considers bronchiolitis to be the first manifestation of recurrent wheezing in infants and children who are susceptible (...) to obstructive airway disease. The second hypothesis suggests that the infection and concomitant inflammatory reaction in the acute phase leads to airway epithelium injury resulting in long-term obstructive airway disease. In line with the latter hypothesis, corticosteroids may have a beneficial effect on the prevention of post-bronchiolitic wheezing. OBJECTIVES: The objective of this review was to evaluate the effect of inhaled corticosteroids, started during the acute phase of bronchiolitis

Cochrane2011

70. Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age.

Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age. BACKGROUND: Acute bronchiolitis is a common respiratory infection and a major cause of morbidity in young children. It is treated with bronchodilators (for example, salbutamol), corticosteroids or humidified air (steam inhalation or cool mist). Steam inhalation is preferred in low-income countries as it is inexpensive and easily available. It is thought to act as a secretolytic agent to lighten (...) secretions in the respiratory tract and relieve respiratory distress. OBJECTIVES: To evaluate the effect of steam inhalation or humidified oxygen to relieve respiratory distress and to evaluate adverse events in children up to three years old with acute bronchiolitis. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 1) which contains the Acute Respiratory Infections Group's Specialised Register, MEDLINE (1950 to February Week 4

Cochrane2011

71. Randomised controlled trial: Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h

Randomised controlled trial: Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h Article Text Therapeutics Randomised controlled trial Repeated dosing of nebulised 5% saline improves

Evidence-Based Medicine (Requires free registration)2011

72. Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses

Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk (...) infants and young children: a systematic review and additional economic modelling of subgroup analyses Wang D, Bayliss S, Meads C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic

Health Technology Assessment (HTA) Database.2011

73. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants

Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants 20646715 2010 09 09 2010 10 08 2011 08 31 1097-6833 157 4 2010 Oct The Journal of pediatrics J. Pediatr. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. 630-4, 634.e1 10.1016/j.jpeds.2010.04.074 To compare the efficacy and safety of 5%, 3%, and 0.9% saline solution for treating acute bronchiolitis in the prehospital setting. This was a double-blind trial including (...) consecutive infants aged <18 months treated in an urban urgent care setting. A total of 165 patients were randomized to receive nebulized 5%, 3%, or 0.9% (normal) saline with epinephrine every 4 hours. The primary efficacy outcome was bronchiolitis severity score improvement at 48 hours (chi2 analysis). Scores and oxygen saturation immediately before and after each treatment were recorded to assess safety. A total of 187 previously healthy infants (median age, 3.1 months) diagnosed with bronchiolitis were

EvidenceUpdates2010

74. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients

Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients 20508211 2010 09 13 2010 09 27 2016 10 19 1535-4970 182 6 2010 Sep 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. 784-9 10.1164/rccm.201002-0211OC Despite the importance of bronchiolitis obliterans syndrome (BOS) in lung transplantation, little is known regarding (...) Med. 2000 Jun;161(6):1937-41 10852770 J Heart Lung Transplant. 2002 Mar;21(3):297-310 11897517 J Heart Lung Transplant. 2002 Jun;21(6):658-66 12057699 Chest. 2002 Jun;121(6):1883-9 12065353 Eur Respir J. 2003 Dec;22(6):1007-18 14680094 Chest. 1984 Dec;86(6):824-9 6437751 J Heart Lung Transplant. 1993 Sep-Oct;12(5):713-6 8241207 Chest. 1995 Apr;107(4):967-72 7705163 Am J Respir Crit Care Med. 2011 Feb 15;183(4):554; author reply 554-5 21325085 Adolescent Adult Aged Bronchiolitis Obliterans etiology

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

75. High Flow Nasal Cannulae Therapy in Infants with Bronchiolitis

High Flow Nasal Cannulae Therapy in Infants with Bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2010

76. Epinephrine and dexamethasone in children with bronchiolitis

Epinephrine and dexamethasone in children with bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2010

77. Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review

Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2010

78. A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department

A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department 19884591 2009 11 03 2009 12 22 2015 11 19 1538-3628 163 11 2009 Nov Archives of pediatrics & adolescent medicine Arch Pediatr Adolesc Med A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department. 1007-12 10.1001/archpediatrics.2009.196 To determine whether nebulized 3% hypertonic (...) saline with epinephrine is more effective than nebulized 0.9% saline with epinephrine in the treatment of bronchiolitis in the emergency department. Randomized, double-blind, controlled trial. Single-center urban pediatric emergency department. Infants younger than 12 months with mild to moderate bronchiolitis. Patients were randomized to receive nebulized racemic epinephrine in either hypertonic or normal saline. The primary outcome measure was the change in respiratory distress, as measured

EvidenceUpdates2010

79. WITHDRAWN. Surfactant therapy for bronchiolitis in critically ill infants.

WITHDRAWN. Surfactant therapy for bronchiolitis in critically ill infants. BACKGROUND: Viral bronchiolitis is a common cause of respiratory failure in infants and children, and accounts for a significant portion of intensive care unit (ICU) admissions during seasonal epidemics. Currently there is no evidence to support the use of anything but supportive care for this disease. Surfactant is a potentially promising therapy; alterations in its composition have been described in bronchiolitis (...) , and it may play a role in the host immunity for this disease. OBJECTIVES: To assess the efficacy of exogenous surfactant for the treatment of bronchiolitis in mechanically ventilated infants and children. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2006, issue 1) which contains the Acute Respiratory Infections Group's Specialized Register; MEDLINE (1966 to Week 1, February 2006); and EMBASE (1990 to September 2005). SELECTION CRITERIA

Cochrane2010